Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 2/20 | 0.40 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.38 |
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | RARG | P13631 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19869779 | 0.81 | BRD4 (0.48) | BRD4BRD9ALDH1A1 | |
| SCHEMBL23783182 | 0.81 | BRD4 (0.43) | BRD4BRD9RXRBRXRABRD7 | |
| SCHEMBL24556507 | 0.76 | HSD17B1 (0.44) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL19869678 | 0.75 | BRD4 (0.49) | BRD4BRD9BRD7BRD2ALDH1A1 | |
| SCHEMBL19869695 | 0.75 | BRD4 (0.60) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL29771992 | 0.74 | RXRB (0.70) | RXRBRXRARARBCAMKK2MCL1 | |
| SCHEMBL1498034 | 0.74 | RXRB (0.70) | RXRBRXRARARBCAMKK2MCL1 | |
| SCHEMBL30031484 | 0.73 | BRD4 (0.43) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL23783402 | 0.73 | BRD4 (0.43) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL23134700 | 0.72 | BRD4 (0.60) | BRD4BRD9BRD7BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | BRD4 17/4885BRD9 1/4885RXRB 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.